EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieVergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study

Yoichi Nakayama, Akira Onishi, Wataru Yamamoto, Ayaka Yoshikawa, Hideyuki Shiba, Naofumi Yoshida, Yonsu Son, Iku Shirasugi, Toshihisa Maeda, Masao Katsushima, Motomu Hashimoto, Yuki Etani und 9 weitere

Clinical and Experimental Medicine · 2024

DOI: 10.1007/s10238-024-01360-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Yoichi Nakayama und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. y_nakayama8@kuhp.kyoto-u.ac.jp. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Antirheumatic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data on the safety of Janus kinase inhibitors (JAKis) in patients with renal impairment are lacking. This study aimed to investigate the safety of JAKis compared to biological (b) DMARDs in patients with rheumatoid arthritis (RA) and renal impairment. We used a multi-centre observational registry of patients with RA in Japan (the ANSWER cohort). We assessed the drug retention rates of b/targeted synthetic DMARDs with different modes of action (tumour necrosis factor inhibitors (TNFis), immunoglobulins fused with cytotoxic T-lymphocyte antigen (CTLA-4-Ig), interleukin-6 receptor inhibitors (IL-6Ris), and JAKis) in patients with RA stratified by pre-treatment estimated glomerular filtration rate (eGFR) levels. The time to discontinuation of bDMARDs or JAKis was analysed using a multivariate Cox proportional hazards model This study included 3775 patients, who were classified into three groups (the normal group (eGFR ≥ 60 mL/min/1.73 m 2 ): 2893 patients; CKDa group (eGFR 45–60 mL/min/1.73 m 2 ): 551; and CKDb group (eGFR < 45 mL/min/1.73 m 2 ): 331). In the CKDb group, the 12-month drug retention rate due to adverse events (AE) was the lowest in patients treated with JAKi (TNFi: 93.1%; IL-6Ri: 94.1%; CTLA-4-Ig: 92.3%; JAKi: 75.1%). In the normal and CKDa groups, drug retention rates due to AE were similar among patients treated with bDMARDs and JAKi. In contrast, drug retention rates due to inefficacy were similar between bDMARDs and JAKis in all groups. In the Cox-proportional model, in the CKDb group, TNFi, IL-6Ri, and CTLA-4-Ig showed lower incidence of drug discontinuation due to AE than JAKis (TNFi: hazard ratio = 0.23 (95% confidence interval 0.09–0.61), IL-6Ri: 0.34 (0.14–0.81), CTLA-4-Ig: 0.36 (0.15–0.89)). JAKis showed the lowest drug retention due to AE in patients with moderate-to-severe and severe renal impairment (eGFR < 45 mL/min/1.73 m 2 ). Physicians should pay more attention to renal function when using JAKis than when using bDMARDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsAntirheumatic AgentsHumansFemaleMaleMiddle AgedAgedJapanGlomerular Filtration RateRenal InsufficiencyAdultCohort StudiesBiological Products

Stichwörter der Autor:innen

ANSWER cohortCKDJanus KinaseRheumatoid Arthritisdrug retentioneGFR

Substanzen

Janus Kinase InhibitorsAntirheumatic AgentsBiological Products

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. y_nakayama8@kuhp.kyoto-u.ac.jp.
  • Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.
  • Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kobe University, Kobe, Japan.

Zitieren

APA

Nakayama, Y., Onishi, A., Yamamoto, W., Yoshikawa, A., Shiba, H., Yoshida, N., Son, Y., Shirasugi, I., Maeda, T., Katsushima, M., Hashimoto, M., Etani, Y., Itami, T., Nozaki, Y., Onizawa, H., Fujii, T., Murakami, K., Murata, K., Tanaka, M., …, & Morinobu, A. (2024). Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01360-w

Vancouver

Nakayama Y, Onishi A, Yamamoto W, Yoshikawa A, Shiba H, Yoshida N, et al. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01360-w

BibTeX
@article{Nakayama2024,
  author = {Nakayama, Yoichi and Onishi, Akira and Yamamoto, Wataru and Yoshikawa, Ayaka and Shiba, Hideyuki and Yoshida, Naofumi and Son, Yonsu and Shirasugi, Iku and Maeda, Toshihisa and Katsushima, Masao and Hashimoto, Motomu and Etani, Yuki and Itami, Tetsu and Nozaki, Yuji and Onizawa, Hideo and Fujii, Takayuki and Murakami, Kosaku and Murata, Koichi and Tanaka, Masao and Matsuda, Shuichi and Morinobu, Akio},
  title = {Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  doi = {10.1007/s10238-024-01360-w}
}
Kostenlos starten →